Brands Capitalize on Creative with Advances in the Ad-Lib.io Platform
Ad-Lib.io, a Smartly.io company and a leading next-generation Creative Management Platform (CMP), announced today the release of the next generation of Personalize™, Ad-Lib.io’s award-winning cookieless platform for creative management, media alignment and creative intelligence all in one place. Personalize 2.0 delivers breakthrough capabilities to accelerate and scale campaign activation while ensuring brand governance and improved campaign addressability cross-channel.
As a result of these advances, advertisers are experiencing a range of ROAS benefits, including:
- 28% reduction in time required to link media and creative strategies in a single digital workspace,
- 4x faster campaign builds with on-brand assets, published and approved automatically,
- 85% fewer clicks to build personalized variants for every audience in their media plan, and
- Up to a week’s advance notice prior to the onset of campaign fatigue, thanks to AI-driven modeling, along with the creative data insights to tune performance at the variant level.
“Scaling campaigns significantly while comfortably reducing production time has been simply delightful,” said Barbara Piras, Group Head of Digital Marketing at TUI Group. “Adding Ad-Lib.io’s technology to our marketing workflow has opened a new world of creative possibilities I’m excited to explore in the future.”
“Our hyperlocal marketing strategy has been instrumental to our success, and Ad-Lib.io is a key partner in helping us scale our reach and creative effectiveness in record time,” said Dean Weaving, Director of Brand Media Operations at Deliveroo. “Their platform has brought our creative and media teams together at a high level of collaboration and coordination, time and time again. We look forward to continuing our work, leveraging their platform, to bring the same relevant, on-target advertising to a multitude of highly differentiated localities.”
“According to a recent WBR Insights survey, only 10% of advertisers felt that their creative and media teams were aligned. This disconnect leads to a number of inefficiencies and sub-optimal results, and it is a core challenge addressed by our platform,” said Oli Marlow Thomas, Ad-Lib.io Founder. “Our goal is to transform the creative production process into one that is easier, faster, more collaborative, data-advised and better aligned to media strategies.”
With Personalize 2.0, advertisers can now execute multi-market activations across channels in fewer steps, integrate with leading media platforms to instantly pull in target audiences and publish approved creatives while reducing the risk of creative rejection. Advertisers can also build targeted creative campaigns and test and learn strategies at scale in minutes, across display, video and social. AI can be leveraged at every step along the way, from asset cropping for quick and easy image editing across channels and formats, to fatigue alerts to prevent premature decline in campaign performance. Best of all, in-line performance reporting reduces the campaign optimization effort to just a few clicks.
Personalize 2.0 is immediately available. Click here for more information on Ad-Lib.io and the Smartly.io family of creative effectiveness capabilities.
About Ad-lib.io
Ad-Lib.io, a Smartly.io company, provides the leading next-generation Creative Management Platform for marketers at the world’s largest brands to enable them to scale their digital creative. Ad-Lib.io connects creative and media workflows using intelligent automation, making it easy and fast to produce and optimize relevant ad creative across all digital channels. These ads are 60% more cost-efficient to produce, according to Ad-LIb.io’s customers, including TUI, Estee Lauder, IG, Pizza Hut and other global brands.. Recently acquired by Smartly.io, Ad-Lib.io was founded by former Google executives who understood the need to close the wide gap between creative concepts and digital media execution.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005295/en/
Contact information
Dina Magdovitz
smartly.io@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
Illumynt Reports Q3 2025 Business Update17.10.2025 15:39:00 EEST | Press release
Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom